Skip to main content

Advertisement

Table 1 Baseline characteristics for men in Prostate Cancer data Base Sweden (PCBaSe)Traject

From: How to measure temporal changes in care pathways for chronic diseases using health care registry data

  Deferred treatment as part of AS ➔ WW model (n = 23,649) Deferred treatment WW (n = 7286) Radical prostatectomy RP (n = 32,537) Radio therapy RT (n = 19,019) Anti-androgen monotherapy AA (n = 7178) Gonadotropin releasing hormone agonists GnRH (n = 29,074) Total (n = 118,743)
Age, median (Q1-Q3) 69 (64–74) 77 (73–81) 63 (59–67) 67 (62–71) 76 (71–81) 77 (71–82) 69 (63–76)
Age, n (%)
  ≤ 55 1008 (4.3) 33 (0.5) 4120 (12.7) 875 (4.6) 55 (0.8) 341 (1.2) 6432 (5.4)
 56–60 2332 (9.9) 116 (1.6) 6942 (21.3) 2403 (12.6) 153 (2.1) 803 (2.8) 12,749 (10.7)
 61–65 4543 (19.2) 296 (4.1) 10,356 (31.8) 4775 (25.1) 475 (6.6) 1959 (6.7) 22,404 (18.9)
 66–70 6172 (26.1) 800 (11.0) 8635 (26.5) 6053 (31.8) 964 (13.4) 3535 (12.2) 26,159 (22.0)
 71–80 8241 (34.8) 3929 (53.9) 2461 (7.6) 4880 (25.7) 3734 (52.0) 13,167 (45.3) 36,412 (30.7)
 81+ 1353 (5.7) 2112 (29.0) 23 (0.1) 33 (0.2) 1797 (25.0) 9266 (31.9) 14,584 (12.3)
Year of diagnosis, n (%)
 1992–1997 558 (2.4) 243 (3.3) 513 (1.6) 245 (1.3) 22 (0.3) 561 (1.9) 2142 (1.8)
 1998–2004 4472 (18.9) 2144 (29.4) 7113 (21.9) 5373 (28.3) 1024 (14.3) 8672 (29.8) 28,798 (24.3)
 2005–2008 5770 (24.4) 2369 (32.5) 9363 (28.8) 4894 (25.7) 1742 (24.3) 9353 (32.2) 33,491 (28.2)
 2009–2011 5969 (25.2) 1679 (23.0) 7911 (24.3) 4804 (25.3) 1841 (25.6) 5893 (20.3) 28,097 (23.7)
 2012–2014 6880 (29.1) 851 (11.7) 7637 (23.5) 3703 (19.5) 2549 (35.5) 4595 (15.8) 26,215 (22.1)
T stage, n (%)
 T1a 2564 (10.8) 440 (6.0) 276 (0.8) 99 (0.5) 25 (0.3) 129 (0.4) 3533 (3.0)
 T1b 963 (4.1) 499 (6.8) 247 (0.8) 194 (1.0) 101 (1.4) 365 (1.3) 2369 (2.0)
 T1c 15,243 (64.5) 2373 (32.6) 20,010 (61.5) 7496 (39.4) 1580 (22.0) 3559 (12.2) 50,261 (42.3)
 T2 4738 (20.0) 2464 (33.8) 10,881 (33.4) 7201 (37.9) 2659 (37.0) 8927 (30.7) 36,870 (31.1)
 T3 0 (0.0) 1362 (18.7) 979 (3.0) 3883 (20.4) 2436 (33.9) 12,517 (43.1) 21,177 (17.8)
 T4 0 (0.0) 49 (0.7) 12 (0.0) 71 (0.4) 280 (3.9) 3002 (10.3) 3414 (2.9)
 TX/Missing 141 (0.6) 99 (1.4) 132 (0.4) 75 (0.4) 97 (1.4) 575 (2.0) 1119 (0.9)
N stage, n (%)
 N0 1831 (7.7) 292 (4.0) 7472 (23.0) 6004 (31.6) 766 (10.7) 1418 (4.9) 17,783 (15.0)
 N1 0 (0.0) 44 (0.6) 278 (0.9) 317 (1.7) 321 (4.5) 1627 (5.6) 2587 (2.2)
 NX 21,818 (92.3) 6950 (95.4) 24,787 (76.2) 12,698 (66.8) 6091 (84.9) 26,029 (89.5) 98,373 (82.8)
Gleason Grade Group /WHO, n (%)
 GGG1 20,019 (84.7) 2860 (39.3) 16,783 (51.6) 6653 (35.0) 1181 (16.5) 3226 (11.1) 50,722 (42.7)
 GGG2 2295 (9.7) 1469 (20.2) 8564 (26.3) 4750 (25.0) 1537 (21.4) 3398 (11.7) 22,013 (18.5)
 GGG3    969 (13.3) 3291 (10.1) 3007 (15.8) 1476 (20.6) 4209 (14.5) 12,952 (10.9)
 GGG2–3 202 (0.9) 257 (3.5) 790 (2.4) 388 (2.0) 168 (2.3) 1331 (4.6) 3136 (2.6)
 GGG4    662 (9.1) 1792 (5.5) 2025 (10.6) 1321 (18.4) 6155 (21.2) 11,955 (10.1)
 GGG5    202 (2.8) 687 (2.1) 1496 (7.9) 1028 (14.3) 6874 (23.6) 10,287 (8.7)
 Only WHO-grade 1096 (4.6) 740 (10.2) 600 (1.8) 671 (3.5) 315 (4.4) 3055 (10.5) 6477 (5.5)
Missing 37 (0.2) 127 (1.7) 30 (0.1) 29 (0.2) 152 (2.1) 826 (2.8) 1201 (1.0)
PSA, median (Q1-Q3) 6.0 (4.2–8.2) 18 (12–26) 6.8 (4.8–10) 10 (6.4–18) 22 (12–47) 45 (19–139) 9.9 (5.8–24)
Mode of detection, n (%)
 Screeningf 10,024 (42.4) 1842 (25.3) 17,060 (52.4) 8119 (42.7) 2020 (28.1) 3912 (13.5) 42,977 (36.2)
 LUTS 7705 (32.6) 2572 (35.3) 7453 (22.9) 5133 (27.0) 3134 (43.7) 12,024 (41.4) 38,021 (32.0)
 Other symptoms 4258 (18.0) 2127 (29.2) 5606 (17.2) 4244 (22.3) 1743 (24.3) 10,962 (37.7) 28,940 (24.4)
 Missing 1662 (7.0) 745 (10.2) 2418 (7.4) 1523 (8.0) 281 (3.9) 2176 (7.5) 8805 (7.4)
CCI, n (%)
 0 15,370 (65.0) 4257 (58.4) 25,259 (77.6) 13,369 (70.3) 4275 (59.6) 16,427 (56.5) 78,957 (66.5)
 1 4228 (17.9) 1435 (19.7) 3955 (12.2) 3172 (16.7) 1461 (20.4) 6179 (21.3) 20,430 (17.2)
 2 2356 (10.0) 945 (13.0) 1971 (6.1) 1511 (7.9) 806 (11.2) 3737 (12.9) 11,326 (9.5)
 3+ 1695 (7.2) 649 (8.9) 1352 (4.2) 967 (5.1) 636 (8.9) 2731 (9.4) 8030 (6.8)
Risk category, n (%)
 1 7546a (31.9) 1001b ‘(13.7) 8985c (27.6) 3735d (19.6) 922e (12.8) 6854e (23.6)   
 2 13,515a (57.1) 1004b ‘(13.8) 9997c (30.7) 1563d (8.2) 870e (12.1) 2585e (8.9)   
 3 2588a (10.9) 947b ‘(13.0) 5094c (15.7) 2285d (12.0) 1495e (20.8) 2855e (9.8)   
 4    1307b ‘(17.9) 5893c (18.1) 2805d (14.7) 1162e (16.2) 1811e (6.2)   
 5    1281b ‘(17.6) 2480c (7.6) 1844d (9.7) 1007e (14.0) 3605e (12.4)   
 6    1746b ‘(24.0) 88c (0.3) 2146d (11.3) 634e (8.8) 2468e (8.5)   
 7        2658d (14.0) 492e (6.9) 1231e (4.2)   
 8        1983d (10.4) 596e (8.3) 7665e (26.4)   
  1. CCI Charlson comorbidity index, LUTS lower urinary tract symptoms
  2. aRisk categories AS1- AS3
  3. bRisk categories WW1-WW6
  4. cRisk categories RP1-RP6
  5. dRisk categories RT1-RT8
  6. eRisk categories ADT1-ADT8
  7. fScreening, prostate cancer detected due to work-up after PSA testing in asymptomatic men